It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Dr. Mercola's Comments:
On June 11 the World Health Organization (WHO) raised its swine flu pandemic alert from a 5 to a 6. Phase 6 is the highest level alert, and reflects the speed with which a virus is spreading -- not its severity.
This classification also allows for a vaccine to qualify for a “fast-track” procedure for licensing and approval, and this process is now ongoing for the swine flu vaccine.
What you may not know, however, is that WHO, together with health officials, regulatory authorities and vaccine manufacturers, have been working since 2007 – long before this new “threat” of swine flu emerged – to “explore a broad range of issues surrounding the regulatory approval of pandemic vaccines.”
According to the WHO website:
“Ways were sought to shorten the time between the emergence of a pandemic virus and the availability of safe and effective vaccines.”
When testing these mock-up vaccines, it is very possible to release the novel influenza virus into the population, as its purpose is to “mimic the novelty of a pandemic virus” and “greatly expedite regulatory approval.”
Originally posted by TrainDispatcher
From that same page...
Vaccine manufacturer GlaxoSmithKline has actually stated:
"Clinical trials will be limited, due to the need to provide the vaccine to governments as quickly as possible. Additional studies will therefore be required and conducted after the vaccine is made available."
And WHO likewise says:
“Time constraints mean that clinical data at the time when pandemic vaccines are first administered will inevitably be limited. Further testing of safety and effectiveness will need to take place after administration of the vaccine has begun
2114 G.3.6.2 Pregnant women
2115 Based on seasonal influenza morbidity pregnant women are considered to constitute a risk group for influenza-related complications and public health authorities might therefore recommend vaccination in pregnant women. On the other hand, pregnant women will most likely not be included in clinical trials with vaccines against novel human influenza viruses. Although inactivated vaccines are considered to cause no harm when administered to pregnant women, the knowledge concerning reproductive toxicity of inactivated pandemic influenza vaccines (as they will be new vaccines perhaps in new formulations) in humans will be limited.
2123 Live attenuated influenza vaccines are usually not recommended during pregnancy, but there might be circumstances where these are used in pregnant women during a pandemic. Women who are immunized with LAIV shortly before or during pregnancy should be monitored and data should be collected on outcomes.
2128 It is unknown whether conclusions from animal studies conducted during nonclinical evaluations of candidate influenza vaccines will apply to humans. As a consequence there will be very limited or no data available regarding safety and efficacy of pandemic influenza vaccines in pregnancy prior to use.
2133 Continuous evaluation of risks and benefits of pandemic influenza vaccines should be established in pregnant women. As a first step more information may be gathered with seasonal influenza vaccines. In this respect, capability of already existing pregnancy registries or currently running epidemiological studies should be evaluated. Studies with pandemic human influenza vaccines should be designed to identify spontaneous abortions, stillbirth, congenital malformations, and any adverse reactions in the neonate that are classified as serious.
Originally posted by TrainDispatcher
The document on the WHO website linked below states that it is common procedure to release pandemic viruses into the population in order to get a jump ahead of the real pandemic, so as to fast track the vaccine for when it is needed.